HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
INBS
Intelligent Bio Solutions Inc.
There isn't enough reported data to score INBS yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
INBS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Unavailable |
INBS's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
INBS PE Valuation
INBS has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
INBS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect INBS's losses to grow, with revenue declining.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
INBS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$8.95 | +$7.55 |
| Q2 2026 | -$11.59 | +$8.41 |
| Q3 2023 | -$1,384.80 | -$84.71 |
| Q2 2023 | -$1,452.00 | -$103.91 |
| Q1 2023 | -$1,273.69 | -$92.14 |
| Q4 2022 | -$803.29 | +$810.26 |
| Q3 2022 | -$1,300.09 | +$313.46 |
INBS has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over INBS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over INBS on profitability, with a higher operating margin.
INBS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.4M | +25% |
| Q2 2026 | $1.1M | +36% |
| Q1 2026 | $1.1M | +18% |
| Q4 2025 | $896.8K | +21% |
| Q3 2025 | $1.1M | +11% |
| Q2 2025 | $843.9K | +16% |
| Q1 2025 | $902.1K | +9.5% |
| Q4 2024 | $741.1K | -3% |
INBS's revenue has grown year over year for seven quarters in a row: $1M last quarter, up 25% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -193% | +77 points |
| Q2 2026 | -346% | +21 points |
| Q1 2026 | -278% | +5.2 points |
| Q4 2025 | -294% | +12 points |
| Q3 2025 | -270% | +3.2 points |
| Q2 2025 | -368% | +19 points |
| Q1 2025 | -283% | +76 points |
| Q4 2024 | -306% | -45 points |
INBS's operating margin was −193% last quarter, up 77 points from the same quarter a year ago, near the top of its range since 2020.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
INBS has the stronger cash trend. Its trailing FCF is down 50% versus its history, compared with HIMS at down 84%.
INBS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$4.3M | -$1.6M |
| Q4 2025 | -$1.6M | +$689K |
| Q3 2025 | -$2.9M | -$530K |
| Q1 2025 | -$2.8M | -$308.8K |
| Q4 2024 | -$2.3M | +$544.4K |
| Q3 2024 | -$2.4M | -$1.1M |
| Q2 2024 | -$2.9M | -$2.4M |
| Q1 2024 | -$2.4M | +$71.9K |
INBS has burned cash in almost every quarter: −$12M over the past year, against −$10M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over INBS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
INBS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +94% | +1.5M shares |
| 1 year | +436% | +2.5M shares |
| 3 years | +50551% | +3.1M shares |
INBS has 3M diluted shares, up 436% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
INBS Net Leverage
INBS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
INBS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.1 | Neutral |
| Stochastic | 25.1 | Neutral |
INBS's weekly RSI is 42 (neutral) and its Stochastic is 25 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
INBS PE vs Healthcare Sector
INBS has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
INBS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.71 | 13% above |
| 20 week MA | $1.98 | 2.5% below |
| 50 week MA | $3.82 | 49% below |
| 100 week MA | $9.38 | 79% below |
| 200 week MA | $95.8 | 98% below |
INBS has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over INBS on returns for 2026, with the stronger performance.
INBS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $25,320.0 | $25,320.0 | 0% |
| 2021 | $25,320.0 | $3,864.0 | -85% |
| 2022 | $3,864.0 | $686.0 | -82% |
| 2023 | $686.0 | $40.6 | -94% |
| 2024 | $40.6 | $14.3 | -65% |
| 2025 | $14.3 | $4.84 | -66% |
| 2026 YTD | $4.84 | $1.93 | -60% |
INBS has finished every year since 2020 lower, and it's down 60% so far in 2026.